ORIC and Cancer Research UK Advance CIP2A Cancer Therapy
ORIC Pharmaceuticals has announced agreement with Cancer Research UK to advance a potential first-in-class CIP2A-targeted therapy into clinical development.
Cancer Research UK Centre For Drug Development | 07/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy